JNJ

227.73

-0.27%↓

ISRG

505.84

-3.26%↓

ABT

105.85

-1.07%↓

MDT

100.64

-0.45%↓

132.22

-1.97%↓

JNJ

227.73

-0.27%↓

ISRG

505.84

-3.26%↓

ABT

105.85

-1.07%↓

MDT

100.64

-0.45%↓

132.22

-1.97%↓

JNJ

227.73

-0.27%↓

ISRG

505.84

-3.26%↓

ABT

105.85

-1.07%↓

MDT

100.64

-0.45%↓

132.22

-1.97%↓

JNJ

227.73

-0.27%↓

ISRG

505.84

-3.26%↓

ABT

105.85

-1.07%↓

MDT

100.64

-0.45%↓

132.22

-1.97%↓

JNJ

227.73

-0.27%↓

ISRG

505.84

-3.26%↓

ABT

105.85

-1.07%↓

MDT

100.64

-0.45%↓

132.22

-1.97%↓

Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Atvērts

2.5 -8.09

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.5

Max

2.73

Galvenie mērījumi
By Trading Economics
Ienākumi	183K -27M
Darbinieki	166
EBITDA	9.4M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+125.26% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 24. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	86M 181M
Iepriekšējā atvēršanas cena	10.59
Iepriekšējā slēgšanas cena	2.5

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

1.23 / 1.45 Atbalsts un pretestība

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 28. janv. 23:51 UTC

Peļņas

Correction to Samsung Fourth-Quarter Net Profit Article

2026. g. 28. janv. 23:49 UTC

Karstas akcijas

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

2026. g. 28. janv. 23:19 UTC

Peļņas

Samsung's Fourth-Quarter Net Profit Beats Consensus

2026. g. 28. janv. 22:43 UTC

Peļņas

Waste Management Logs Higher 4Q Profit as Revenue Rises

2026. g. 29. janv. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

2026. g. 29. janv. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

2026. g. 29. janv. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

2026. g. 29. janv. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

2026. g. 28. janv. 23:49 UTC

Tirgus saruna

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

2026. g. 28. janv. 23:30 UTC

Tirgus saruna

Tesla to Use Car Factory for Robot Aims -- Market Talk

2026. g. 28. janv. 23:28 UTC

Peļņas

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

2026. g. 28. janv. 23:26 UTC

Peļņas

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

2026. g. 28. janv. 23:21 UTC

Peļņas

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

2026. g. 28. janv. 23:18 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

2026. g. 28. janv. 22:58 UTC

Peļņas

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

2026. g. 28. janv. 22:48 UTC

Tirgus saruna

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

2026. g. 28. janv. 22:45 UTC

Peļņas

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

2026. g. 28. janv. 22:44 UTC

Peļņas

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

2026. g. 28. janv. 22:43 UTC

Peļņas

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

2026. g. 28. janv. 22:41 UTC

Peļņas

Karstas akcijas

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

2026. g. 28. janv. 22:41 UTC

Tirgus saruna

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

2026. g. 28. janv. 22:41 UTC

Peļņas

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

2026. g. 28. janv. 22:40 UTC

Peļņas

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 28. janv. 22:39 UTC

Peļņas

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

2026. g. 28. janv. 22:38 UTC

Peļņas

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

2026. g. 28. janv. 22:37 UTC

Peļņas

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

2026. g. 28. janv. 22:35 UTC

Peļņas

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

2026. g. 28. janv. 22:26 UTC

Tirgus saruna

Peļņas

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

2026. g. 28. janv. 22:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 28. janv. 22:20 UTC

Tirgus saruna

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

125.26% augšup

Prognoze 12 mēnešiem

Vidējais 6.6 USD 125.26%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.23 / 1.45Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.